Stephen Opat
Stephen Opat
Verified email at monash.edu
Title
Cited by
Cited by
Year
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
V Goede, K Fischer, R Busch, A Engelke, B Eichhorst, CM Wendtner, ...
New England Journal of Medicine 370 (12), 1101-1110, 2014
15242014
Obinutuzumab for the first-line treatment of follicular lymphoma
R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, ...
New England Journal of Medicine 377 (14), 1331-1344, 2017
4052017
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...
New England journal of medicine 380 (23), 2225-2236, 2019
4022019
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
R Kridel, B Meissner, S Rogic, M Boyle, A Telenius, B Woolcock, ...
Blood, The Journal of the American Society of Hematology 119 (9), 1963-1971, 2012
3382012
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
3302019
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
A Catalano, MA Dawson, K Somana, S Opat, A Schwarer, LJ Campbell, ...
Blood, The Journal of the American Society of Hematology 110 (12), 4073-4076, 2007
1362007
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ...
Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019
1332019
The recognition of HLA-B27 by human CD4+ T lymphocytes
LH Boyle, JC Goodall, SS Opat, JSH Gaston
The Journal of Immunology 167 (5), 2619-2624, 2001
1222001
The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial
C Tam, AP Grigg, S Opat, M Ku, M Gilbertson, MA Anderson, JF Seymour, ...
Blood, The Journal of the American Society of Hematology 126 (23), 832-832, 2015
1132015
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ...
Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017
1122017
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma
CY Cheah, KE Herbert, K O'rourke, GA Kennedy, A George, PL Fedele, ...
British journal of cancer 111 (6), 1072-1079, 2014
1052014
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
J Shortt, DH Oh, SS Opat
New England Journal of Medicine 368 (1), 90-92, 2013
1032013
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ...
Blood 136 (18), 2038-2050, 2020
702020
Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin Lymphomas
F Morschhauser, G Salles, P McKay, H Tilly, A Schmitt, J Gerecitano, ...
Hematological Oncology 35, 24-25, 2017
662017
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ...
The Lancet Oncology 21 (11), 1433-1442, 2020
652020
Rituximab is associated with improved survival for aggressive B cell CNS lymphoma
G Gregory, A Arumugaswamy, T Leung, KL Chan, M Abikhair, C Tam, ...
Neuro-oncology 15 (8), 1068-1073, 2013
632013
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ...
The Lancet Oncology 19 (11), 1530-1542, 2018
622018
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open …
O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ...
The Lancet Oncology 21 (9), 1188-1200, 2020
612020
Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the …
RE Marcus, AJ Davies, K Ando, W Klapper, S Opat, CJ Owen, EH Phillips, ...
Blood 128 (22), 6, 2016
582016
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis
K Wolyniec, J Shortt, E de Stanchina, Y Levav-Cohen, O Alsheich-Bartok, ...
Blood, The Journal of the American Society of Hematology 120 (4), 822-832, 2012
572012
The system can't perform the operation now. Try again later.
Articles 1–20